Clinical trialNCT05950464RecruitingPhase 1Interventional

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

SponsorNational Cancer Institute (NCI)Enrollment65Recurrent Endometrial CarcinomaRecurrent Endometrial Clear Cell AdenocarcinomaRecurrent Endometrial Endometrioid AdenocarcinomaRecurrent Endometrial Low Grade Endometrioid AdenocarcinomaRecurrent Ovarian Clear Cell AdenocarcinomaRecurrent Ovarian Endometrioid Adenocarcinoma+3 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. M1774 and ZEN-3694 combined together has demonstrated to be better than either drug alone in killing ovarian tumor cells.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Fiona Simpkins
NRG Oncology
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Augusta University Medical Center
Augusta, Georgia, United States
Suspended
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Katherine C. Kurnit
Recruiting
University of Iowa/holden Comprehensive Cancer Center
Iowa City, Iowa, United States
David P. Bender
Recruiting
Wayne State University/karmanos Cancer Institute
Detroit, Michigan, United States
Suspended
University of New Mexico Cancer Center
Albuquerque, New Mexico, United States
Carolyn Y. Muller
Recruiting
Case Western Reserve University
Cleveland, Ohio, United States
Active, not recruiting
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Peter G. Rose
Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
John L. Hays
Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Lauren E. Dockery
Recruiting
Nrg Oncology
Philadelphia, Pennsylvania, United States
Fiona Simpkins
Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Mitchell I. Edelson
Recruiting
University of Pennsylvania/abramson Cancer Center
Philadelphia, Pennsylvania, United States
Fiona Simpkins
Recruiting
Women and Infants Hospital
Providence, Rhode Island, United States
Cara A. Mathews
Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
William H. Bradley
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BET Bromodomain Inhibitor ZEN-3694 →Tuvusertib

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 18 Dec 2023
Primary completion: 30 Jun 2027
Completion: 30 Jun 2027
Last update posted: 9 Jul 2026
Registered enrollment: 65
Registry id: NCT05950464

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.